Growth capital prescribed to boost SEDA’s expansion
SEDA Pharma Development Services Ltd
SEDA Pharma Development Services Ltd are specialists when it comes to developing pharmaceutical drugs for medical trials. Paul Stott, CEO, and his team have spent years developing their state-of-the-art facilities in Cheadle.
Having built a strong relationship, we were able to support their growth aspirations with a £5m Growth Capital loan.
SEDA saw an opportunity to support their clients into the next phase of the development process by offering a good manufacturing processes (GMP) service. This meant they could design a drug and manufacture it for clinical trials.
With our funding, they're building a state-of-the-art manufacturing facility, which will meet industry standard quality specifications.
Having solid financial backing from Santander has supported our rapid expansion without a loss of control. This allows us to maintain our laser focus on delivering long term client value and exceptional product quality without the distraction of having to meet short term investor demands.
CEO, SEDA Pharma Development Services Ltd
This will allow SEDA to go from strength to strength as they integrate emerging and innovative technologies throughout the new site. They also anticipate they'll need to expand their team of specialists, with up to 100 new roles being created.
We’re delighted to see a company that has banked with us since inception grow so rapidly and have such an exciting future. SEDA are making a significant and positive contribution to medical science globally. As their banking provider, we’re pleased to be able to support this next phase of their growth.
Relationship Director, Santander
Related content
